CA2656630A1 — Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoic acid
Assigned to Bayer Pharma AG · Expires 2008-01-10 · 18y expired
What this patent protects
The present invention relates to an aqueous pharmaceutical formulation comprising 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl] benzoic acid or a salt thereof. The present invention relates particularly to an aqueous pharmaceutical formulation comprising…
USPTO Abstract
The present invention relates to an aqueous pharmaceutical formulation comprising 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl] benzoic acid or a salt thereof. The present invention relates particularly to an aqueous pharmaceutical formulation comprising 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]phenethyl}amino)methyl] benzoic acid or a salt thereof and amino-2(hydroxymethyl)-2-propanediol-1,3(trometamol).
Drugs covered by this patent
- Acetadote (Acetylcysteine) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.